DiamiR DiamiR, a molecular diagnostic company, develops innovative blood-based tests for early detection &

DiamiR, LLC is a privately held molecular diagnostic company focused on developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer's disease, Parkinson’s disease, other neurodegenerative diseases, and cancer. The proprietary technology is based on quantitative analysis of circulating organ-enriched miRNAs in plasma and can be used for screening, patient stratification as well as disease and treatment monitoring.

07/09/2015

Available to own on Digital Download August 18, 2015 and DVD on September 1, 2015.

11/05/2014

DiamiR announces publication and discusses Universal Screening Test. See the press release: http://www.marketwired.com/press-release/diamir-announces-publication-discusses-merits-universal-screening-test-based-on-organ-1963621.htm

MONMOUTH JUNCTION, NJ--(Marketwired - November 03, 2014) - DiamiR Biosciences Corp., a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today the publication entitled " Universal Screening Test based on analysis of circulating organ-enriched microRNAs: a n…

The Alz Walk today was an amazing experience for Team DiamiR! Thank you to everyone who came out and contributed to the ...
10/19/2014

The Alz Walk today was an amazing experience for Team DiamiR! Thank you to everyone who came out and contributed to the cause.

5.2 million Americans are currently living with Alzheimer’s disease and that number is expected to grow to 9 million by ...
09/08/2014

5.2 million Americans are currently living with Alzheimer’s disease and that number is expected to grow to 9 million by 2050 – unless we do something about it now. Join Team DiamiR in the NYC Walk to End Alzheimer's! http://act.alz.org/goto/DiamiR 's

The Alzheimer's Association Walk to End Alzheimer's is the world's largest event to raise awareness and funds for Alzheimer's care, support and research.

07/15/2014

DiamiR received a grant from The Michael J. Fox Foundation for Parkinson's Research. See the press release: http://www.marketwired.com/press-release/diamir-announces-grant-from-the-michael-j-fox-foundation-parkinsons-research-advance-1929377.htm

MONMOUTH JUNCTION, NJ--(Marketwired - July 14, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the award of a grant from The Michael J. Fox…

Address

Monmouth Junction, NJ
08852

Alerts

Be the first to know and let us send you an email when DiamiR posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to DiamiR:

Share